Skip to main content

Navigation group

Type at least 3 characters
316 articles

Articles

Original Research

Accepted on 12 Nov 2024

Impact on parasitemia, survival time and pro-inflammatory immune response in mice infected with Plasmodium berghei treated with Eleutherine plicata

in Pharmacology of Infectious Diseases

  • AntĂ´nio Rafael Quadros Gomes
  • Ana Laura Gadelha Castro
  • Gleison Gonçalves Ferreira
  • Heliton Patrick Cordovil Brigido
  • Everton Luiz Pompeu Varela
  • Valdicley Vieira Vale
  • Liliane Carneiro
  • Maria Fani Dolabela
  • Sandro Percario
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1484934

Brief Research Report

Published on 30 Oct 2024

First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion

in Pharmacology of Infectious Diseases

  • Paul Laffont-Lozes
  • Tayma Naciri
  • Alix Pantel
  • AurĂ©lie Martin
  • Anne-Sophie Pruvot-Occean
  • Vincent Haignere
  • Paul Loubet
  • Albert Sotto
  • Romaric Larcher
First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1347306
  • 142 views

Brief Research Report

Published on 28 Oct 2024

Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study

in Pharmacology of Infectious Diseases

  • RubĂ©n MartĂ­n-Escolano
  • Ana Virseda-Berdices
  • Juan Berenguer
  • Juan González-GarcĂ­a
  • Oscar Brochado-Kith
  • Amanda Fernández-RodrĂ­guez
  • Cristina DĂ­ez
  • Victor Hontañon
  • The Marathon Study Group
  • Salvador Resino
Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1341612
  • 243 views